Skip to main content
. Author manuscript; available in PMC: 2020 Aug 19.
Published in final edited form as: Nature. 2020 Feb 19;579(7797):130–135. doi: 10.1038/s41586-020-2015-4

Figure 3: ILC2s stimulate tissue-specific cancer immunity by recruiting intratumoral dendritic cells.

Figure 3:

(a) Tumor weight, volume, and survival in orthotopic and subcutaneous PDAC mice treated with vehicle or recombinant IL33 (rIL33). (b) Tumor weight and volume in orthotopic and subcutaneous PDAC mice treated with vehicle or recombinant IL18 (rIL18). (c) Gating, frequency, and number of ILC2s in rIL33-treated orthotopic PDAC mice (DLN vehicle, n=13; tumor vehicle, n=12). (d) Gating and frequency of CD103+ dendritic cells (DCs) in tumors of rIL33-treated orthotopic PDAC mice. (e) Tumor weight, volume, and (f) frequency of CD103+ DCs in tumors of rIL33-treated wild-type (WT) and ILC2 deficient orthotopic PDAC mice. (g) Tumor volume in rIL33-treated WT and CD103+ DC deficient Batf3−/− orthotopic PDAC mice. (h) Migration of purified DCs towards Ccl5. Data were collected at 5 (c, d) and 7 (e, f) weeks post tumor implantation. Horizontal bars mark medians; error bars mark s.e.m. Data were pooled from ≥2 independent experiments, with n≥3/group; n and data points denote individual mice analyzed separately or (h) individual replicates. P values were determined by two-sided log-rank test (a, survival curve), two-way ANOVA (a, b, e, g, tumor volume), and two-tailed Mann-Whitney test (a-f, h).